DRIO

DARIOHEALTH CORP

Healthcare | Micro Cap

-$0.65

EPS Forecast

$5.04

Revenue Forecast

Announcing earnings for the quarter ending 2026-09-30 soon

DarioHealth’s Partner Push: A Hypertension Play That Bets on Enrollments to 2024

DRIO, the ticker for DarioHealth Corp, unveils a pivot from direct-to-consumer to payer-style scale through strategic partnerships. The company announced a new agreement with a large regional health plan to deliver its digital hypertension solution to more than 160,000 plan members, with the plan slated to launch in late July 2023. No EPS figure or EPS consensus was provided in this release, as the document centers on partnerships and preliminary revenue, not quarterly earnings per share. Still, investors will be calibrating the numbers against a revenue forecast implied by the six-month and quarterly results and the potential impact of these contracts on future profitability and the stock’s multiple.

Key developments at a glance

  • Partnership expansion: A new arrangement with a large regional health plan to deliver Dario’s hypertension program to 160,000+ members. The Plan intends to launch in late July 2023.
  • Product and channel strategy: Dario’s solution for hypertension sits within its cardiometabolic product suite, emphasizing a consumer-centric, outcomes-focused approach and a streamlined implementation path for scale.
  • Preliminary revenue signal: For the quarter ended June 30, 2023, DarioGuided’s unaudited revenue guidance sits between $6.0 million and $6.15 million, with six-month revenue between $13 million and $13.15 million. The company notes a drag from fewer milestone deliveries in strategic partnerships.
  • Cash and balance sheet: Preliminary cash and cash equivalents stood at $52.6 million as of June 30, 2023.
  • Strategic wins: Notable contracts with MedOne Pharmacy Benefits Solution (attributed to Sanofi) and the Plan (attributed to Solera), both expected to contribute to 2023 revenue and mark milestone achievements for their respective partnerships.
  • Product delivery milestone: The private-labeled Aetna platform was delivered on schedule in Q2 2023, with opportunities for additional revenue in the second half of the year; enrollment is anticipated to begin in 2024.
  • Guidance context: Management emphasizes that the figures are preliminary unaudited estimates and that the forward-looking statements reflect expectations as of the press date. The company notes that actual results may differ materially and does not commit to updating outlook until the next quarterly results release.

Financial snapshot and takeaways

The press release presents a revenue-centric snapshot rather than a traditional earnings narrative. For readers tracking an earnings surprise or an EPS consensus, the document does not provide quarterly EPS data, nor does it present a formal earnings surprise metric. Instead, the company emphasizes revenue momentum in its B2B channel—described as the tenth straight quarter of growth in that channel—alongside aforeseen revenue contributions from strategic partnerships and platform rollouts.

In terms of revenue visibility, the six-month window ending June 30, 2023 is guided toward roughly $13.0–$13.15 million, reflecting a deliberate shift away from higher direct-to-consumer activity toward partner-driven monetization. The company also notes that revenue from strategic partnerships was below expectations in Q2, due to fewer milestone deliveries than anticipated. Such dynamics imply that the near-term revenue mix could be volatile as milestone-driven revenue accrues more meaningfully later in the year.

Strategic context: a move toward the partner channel and enrollment upside

The Dario strategy leans into partnerships as a lever for scale and recurring revenue. The MedOne and Solera-linked wins signal a maturation of the company’s partner network, which could translate into sustained growth if these relationships translate into durable revenue streams in 2023 and beyond. The private-labeled Aetna platform’s delivery trajectory further anchors the company’s ability to monetize through payer-aligned products, with member enrollment anticipated to start in 2024—opening what management calls a potentially larger opportunity for membership, depending on partner sell-through.

Management characterizes the plan as a “winning proposition for payers,” highlighting improved hypertension outcomes and an engagement model designed to sustain member involvement. The tone suggests a shift from one-off pilot programs toward scalable deployments that can be expanded across partner networks, potentially lifting the revenue forecast trajectory and creating a path toward stabilized cash generation if the enrollment and utilization statistics meet expectations.

Leadership view and sector implications

CEO Erez Raphael frames the partner channel as a core growth engine, emphasizing progress toward scale with key strategic partners. The commentary implies a belief that payer partnerships can unlock durable revenue streams beyond initial deployment milestones. If the company can translate plan enrollments into realized revenue and maintain patient engagement, the trajectory could influence peer players in the digital health and cardiometabolic space, where payer-facing models remain a focal area of investor interest.

The release also reinforces the usual industry caveats: the near-term results are preliminary and unaudited, with forward-looking statements subject to risk factors. The absence of discrete earnings per share data means the stock would likely be evaluated on the revenue trajectory and the strategic value of partnerships rather than a quarterly EPS beat or miss. In other words, this is less about a one-quarter surprise and more about whether the payer-channel thesis can produce a sustainable earnings cadence over time.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is positioned as a digital health company focused on chronic condition management through a user-centric, multi-chronic-condition digital therapeutics platform. Its suite covers diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health, with emphasis on data-driven interventions and coaching. The press release underscores a strategy built around partner-driven revenue and platform-scale opportunities, with ongoing attention to how these relationships translate into measurable growth.

Disclaimer and forward-looking statements

The document includes the standard forward-looking statements disclaimer, noting that the figures are preliminary, unaudited estimates and that actual results may differ materially. The company does not commit to updating its outlook until its next quarterly results release, which leaves room for sentiment shifts as more data becomes available on enrollment, milestone deliveries, and platform monetization.

Bottom line: what this portends for DRIO and peers

The press release signals a deliberate pivot toward payer-aligned business lines and scaled enrollments. If the 2024 enrollment rollout proceeds as planned and partner-driven revenue compounds, DRIO could see a more predictable revenue mix, even if near-term earnings per share remain undefined in this particular communication. For investors, the lesson is not a slam-dunk earnings surprise or a single-quarter EPS beat; it is a test of execution: can Dario convert these partnerships into durable growth, and will the sector’s other players follow suit with similarly scalable, payer-focused strategies?